Printer Friendly

TEVA PHARMACEUTICALS TO MARKET COLUMBIA LABORATORIES' WOMEN'S HEALTH CARE PRODUCTS IN ISRAEL

 TEVA PHARMACEUTICALS TO MARKET COLUMBIA LABORATORIES'
 WOMEN'S HEALTH CARE PRODUCTS IN ISRAEL
 HOLLYWOOD, Fla., June 12 /PRNewswire/ -- Columbia Laboratories, Inc. (AMEX: COB) today announced that they have signed a licensing and distribution agreement with Teva Pharmaceutical Industries Limited under which Teva will be the exclusive marketer of Replens(R) and Columbia's other women's health care products in Israel. Under the agreement, Columbia will manufacture the product, and Teva will market and distribute it.
 "We are extremely pleased that our product will be marketed by Teva, one of the most prestigious and innovative pharmaceutical organizations," said Norman M. Meler, Columbia's president and chief executive officer. "We are looking forward to a successful introduction of Replens in Israel by Teva."
 Replens, available to consumers without a prescription, is a non- hormonal product that treats the problem of vaginal dryness with a sustained release moisturizer. Vaginal dryness is estimated to affect more than 70 million women in the United States and Europe.
 Columbia Laboratories, Inc. is a U.S.-based international pharmaceutical company, established in 1987, dedicated primarily to developing and marketing women's health care products based on its patented bioadhesive drug delivery system.
 -0- 6/12/92
 /CONTACT: Margaret Roell, chief financial officer of Columbia Laboratories, 305-985-6545/
 (COB) CO: Columbia Laboratories, Inc.; Teva Pharmaceutical Industries Limited ST: Florida IN: MTC SU: LIC


AW-JB -- FL003 -- 9563 06/12/92 09:32 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 12, 1992
Words:229
Previous Article:COLUMBIA LABORATORIES EXPANDS WORLDWIDE MARKETING OF REPLENS(R) LOGOS AGREEMENT
Next Article:BG&E TO PARTICIPATE IN CHESAPEAKE CONSORTIUM TO PROMOTE DEVELOPMENT OF ELECTRIC VEHICLES
Topics:


Related Articles
MARION MERRELL DOW AND TEVA TO COLLABORATE ON MARKETING OF MULTIPLE SCLEROSIS TREATMENT
MARION MERRELL DOW AND TEVA TO COLLABORATE ON MARKETING OF MULTIPLE SCLEROSIS TREATMENT
HOECHST MARION ROUSSEL TO COLLABORATE WITH TEVA ON MULTIPLE SCLEROSIS TREATMENT FOR EUROPE, OTHER MARKETS
MEDI-JECT ENTERS INTO A LICENSING AGREEMENT WITH TEVA FOR THE DEVELOPMENT OF A NEEDLE-FREE DRUG DELIVERY SYSTEM TO TREAT MULTIPLE SCLEROSIS
FDA Grants Marketing Clearance for COPAXONE (Glatiramer Acetate for Injection) for Reducing Relapses
AAI Signs Drug Development Agreement With Teva
Merck Establishes New Human Health Subsidiary in Israel
Ranbaxy Announces the Launch of Quinapril Tablets by Teva, Based on an Agreement Between Ranbaxy and Teva.
Upsher-Smith Launches New Vandazole(TM) (Metronidazole Vaginal Gel, 0.75%) for Bacterial Vaginosis.
FDA APPROVES TEVA'S ANDA TO MARKET GENERIC VERSION OF ZOCOR.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters